Table 3.

Measures of endothelial function from baseline to 240 min.

	Whole group		Males		Females
	SFA	SFA + LC n-3 PUFA	SFA	SFA + LC n-3 PUFA	SFA	SFA + LC n-3 PUFA
FMD (%)
Baseline	5.36 ± 0.48	5.23 ± 0.46	4.35 ± 0.50	4.44 ± 0.43	6.37 ± 0.74	6.01 ± 0.76
Δ 240 min	−0.62 ± 0.27†	0.73 ± 0.23*†	−0.86 ± 0.31†	0.51 ± 0.36*	−0.39 ± 0.43	0.94 ± 0.27*†
NOx (μM)
Baseline	24.0 ± 1.4	23.3 ± 1.1	24.3 ± 2.3	22.2 ± 1.4	23.7 ± 1.4	24.3 ± 1.6
Δ 240 min	−3.8 ± 0.7†	−3.1 ± 0.9†	−4.6 ± 1.0†	−2.4 ± 0.9†	−3.0 ± 0.8†	−3.9 ± 1.6†
ET-1 (ng/ml)
Baseline	1.07 ± 0.09	1.04 ± 0.09	1.15 ± 0.14	1.15 ± 0.12	0.99 ± 0.12	0.92 ± 0.12
Δ 240 min	−0.07 ± 0.08	−0.06 ± 0.07	−0.05 ± 0.10	−0.02 ± 0.08	−0.09 ± 0.12	−0.11 ± 0.11

Data are presented as mean ± SEM. FMD; flow-mediated dilatation; NOx, total nitrites; ET-1, endothelin-1. A significant difference from SFA is denoted by * whilst a significant difference in the measures of endothelial function from baseline is notated by † (both P < 0.05). Outcome measures were available for a minimum of fourteen males and fourteen females.